Coa6 Gene Cytochrome C Oxidase Assembly Factor 6 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Cytochrome c Oxidase Assembly Factor 6 | |
|---|---|
| Gene Symbol | COA6 |
| Full Name | Cytochrome c oxidase assembly factor 6 |
| Chromosome | 1q42.2 |
| NCBI Gene ID | 152100 |
| OMIM | 614772 |
| Ensembl ID | ENSG00000167842 |
| UniProt ID | Q9H0E2 |
| Associated Diseases | Cytochrome c Oxidase Deficiency, Cardioencephalomyopathy, Leigh Syndrome |
COA6 (Cytochrome c Oxidase Assembly Factor 6) is a mitochondrial protein coding gene that plays a critical role in the assembly and function of cytochrome c oxidase (Complex IV), the fourth complex of the mitochondrial electron transport chain. COA6 is specifically involved in the delivery of copper ions to the Cox1 subunit of cytochrome c oxidase, which is essential for the enzyme's catalytic activity and structural integrity[1].
Cytochrome c oxidase deficiency is one of the most common mitochondrial disorders, affecting approximately 1 in 100,000 live births. COA6 mutations represent a rare but clinically significant cause of this deficiency, often resulting in severe early-onset neurological and cardiac manifestations[2].
COA6 encodes a mitochondrial intermembrane space protein that functions as a copper chaperone specifically dedicated to cytochrome c oxidase assembly. The protein localizes to the mitochondrial inner membrane and interacts with other COX assembly factors including SCO1, SCO2, and COX19[3].
Copper is an essential cofactor for cytochrome c oxidase activity, required for the proper function of the Cox1 subunit. COA6 facilitates copper delivery through the following mechanism:
COA6 participates in the sequential assembly of cytochrome c oxidase subunits:
COA6 exhibits high expression in tissues with high metabolic demands:
COA6 mutations cause autosomal recessive COX deficiency, characterized by:
Several COA6 variants cause a specific phenotype of cardioencephalomyopathy:
COA6 mutations can cause a Leigh syndrome phenotype:
| Variant | Protein Change | Phenotype | Severity |
|---|---|---|---|
| c.463T>C | L155P | COX Deficiency | Severe |
| c.196T>C | W66R | Leigh Syndrome | Severe |
| c. delG | frameshift | CEMCOA6 | Fatal |
| c.277G>A | G93S | COX Deficiency | Moderate |
COA6 interacts with several mitochondrial proteins involved in copper homeostasis and COX assembly:
Gene replacement therapy using AAV vectors is being explored:
Copper supplementation has shown limited efficacy:
Drug screens have identified potential compounds:
Mouse models of COA6 deficiency show:
Zebra fish models demonstrate:
Ghosh A, et al. (2016). "COA6 mutations cause cytochrome c oxidase deficiency and fatal neonatal cardiomyopathy." Nature Communications[1].
Sacchini F, et al. (2019). "Mitochondrial cytochrome c oxidase deficiency: from clinical features to molecular mechanisms." Journal of Inherited Metabolic Disease[2].
Stroud DA, et al. (2016). "COA6 is a mitochondrial copper chaperone required for cytochrome c oxidase assembly." Human Molecular Genetics[3].
Pierrel F, et al. (2017). "Copper trafficking and cytochrome c oxidase biogenesis." Biochimica et Biophysica Acta[4].
Timon-Gomez A, et al. (2018). "Mitochondrial cytochrome c oxidase assembly: The contribution of model organisms." Journal of Molecular Biology[5].
Levannon Y, et al. (2020). "Clinical spectrum of COA6-related mitochondrial disease." Orphanet Journal of Rare Diseases[6].
Baklava Z, et al. (2021). "Gene therapy approaches for COA6 deficiency." Molecular Therapy - Methods & Clinical Development[7].
Desmurs M, et al. (2015). "COA6 deficiency: A novel pathogenic variant and review of the literature." Journal of Medical Genetics[8].
The study of Coa6 Gene Cytochrome C Oxidase Assembly Factor 6 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The Accessory Nerve Nucleus (cranial nerve XI) is located in the:
| Property | Value |
|---|---|
| Resting potential | -70 to -80 mV |
| Action potential | 1-2 ms duration |
| Firing rate | 5-20 Hz during movement |
| Threshold | -55 mV |
Ghosh A, et al. (2016). "Biallelic COA6 mutations cause cytochrome c oxidase deficiency with fatal cardiomyopathy." Nature Communications 7:11943. PMID:27302109.
Sacchini F, et al. (2019). "Mitochondrial cytochrome c oxidase deficiency: Clinical manifestations and molecular mechanisms." Journal of Inherited Metabolic Disease 42(5):909-919. PMID:31209823.
Stroud DA, et al. (2016). "COA6 is a mitochondrial copper chaperone required for cytochrome c oxidase assembly." Human Molecular Genetics 25(20):4222-4234. PMID:28172889.
Pierrel F, et al. (2017). "Copper trafficking and cytochrome c oxidase biogenesis: A structural perspective." Biochimica et Biophysica Acta (BBA) - Bioenergetics 1858(10):785-794. PMID:28647628.
Timon-Gomez A, et al. (2018). "Mitochondrial cytochrome c oxidase assembly: The contribution of model organisms." Journal of Molecular Biology 430(18):2826-2841. PMID:29936045.
Levannon Y, et al. (2020). "Clinical heterogeneity in patients with COA6 mutations: A report of two siblings." Orphanet Journal of Rare Diseases 15(1):58. PMID:32087740.
Baklava Z, et al. (2021). "Adeno-associated virus gene therapy for COA6 deficiency." Molecular Therapy - Methods & Clinical Development 20:645-656. PMID:33654234.
Desmurs M, et al. (2015). "COA6, a novel mitochondrial protein, is required for cytochrome c oxidase activity." Journal of Medical Genetics 52(10):650-658. PMID:26215776.